Metrics as of 10/13/2026, 06:50 PM (Berlin time), refresh in progress.
Nano-X Imaging Ltd.
Nano-X Imaging Ltd. specializes in developing a commercial-grade tomographic imaging device that incorporates an innovative digital X-ray source, which leverages a digital micro-electro-mechanical systems (MEMS) semiconductor cathode. Beyond its hardware focus, the company also delivers teleradiology services and…
1D
+0.5%
1W
-16.7%
1M
-29.2%
6M
-79.2%
YTD
-81.7%
1Y
-87.4%
2Y
-91.5%
5Y
-97.7%
10Y
–
Next earnings date
19/11/2026 (in 33 days)
Volatility around earnings
~56% stronger price swings than usual
PRICE TARGET LOW
US$3.00
CONSENSUS
US$3.00
MEDIAN
US$3.00
PRICE TARGET HIGH
US$3.00
0
STRONG BUY
4
BUY
2
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 17/08/2026
P/E
-0.3
P/B
0.49
EV/EBITDA
-0.14
RETURN ON EQUITY
-76.6%
NET MARGIN
-1,335.1%
DEBT/EQUITY
0.11
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
91.9%
FLOAT SHARES
63,976,344
AVG. DAILY VOLUME (30D)
1,251,049
Gofman Feler Marina
Yahav Attias Gali
saban sharon
Nathansohn Guy
Aharon Cohen Tamar
Nano-X Imaging Ltd. is a company in the Healthcare sector, Medical - Devices industry, headquartered in Israel.
The CEO is Erez I. Meltzer, the company employs around 197 people.
The IPO was on 21/08/2020; the stock trades on NASDAQ under the ticker NNOX.
6 analysts rate the stock, the consensus is Buy (as of 17/08/2026).
The average price target is US$3.00, ranging from US$3.00 to US$3.00, with a median of US$3.00.
This is an external assessment, not a statement by Market Jury.
The next earnings date is 19/11/2026.
Around past earnings, price swings were roughly 56% stronger than usual.
No, Nano-X Imaging currently does not pay a dividend.
Comparable stocks include Abbott Laboratories, Medtronic, Stryker, Boston Scientific, Edwards Lifesciences, Siemens Healthineers, DexCom and GE HealthCare Technologies.
Clicking "Analyze stock" lets five strategies assess Nano-X Imaging against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.